This is a working overview of PPARδ agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-17. Anything still debated is marked as such rather than presented as settled.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
In early February 2025, Michael McFaul, a Stanford University political science professor and former US ambassador to Russia from 2012 to 2014, wrote via The Dispatch that Trump still viewed China as a major rival during his second term. McFaul criticised the second Trump administration for risking its chances to win "Cold War 2.0". He further criticised the administration's foreign policy decisions—for example, calling Canada a potential 51st state candidate, announcing possibility of obtaining Greenland from a NATO ally Denmark by either sale or military force, and attempts to shut down the United States Agency for International Development (USAID)—for giving China and its ally Russia more advantage and risking ties with longtime US allies. McFaul further wrote, "We will not be able to win Cold War 2.0 on our own." An academic Tim Zajontz in his June 2025 article about Kenya's relations with China and the US noted that the Africa theatre "is not solely reactive to, but co-constitutive of, the Second Cold War". Zajontz further noted how alarming President Trump's second term was to "Kenya's geopolitical vulnerability" and how willing Trump would disengage from "longstanding security cooperation with Kenya" as part of his "disruptive foreign policy arsenal".
=== Jabbar Trussell Braverman === Jabbar Trussell (Tyree Brown) is Jasmine and Crosby's son. He is five years old during the show's first season. He is recurring in season one, but is promoted to a regular role for all subsequent seasons.
=== Lipedema stages === Lipedema is classified by stage: Stage 1: Normal skin surface with enlarged hypodermis (lipedema fat). Stage 2: Uneven skin with indentations in fat and larger hypodermal masses (lipomas). Stage 3: Bulky extrusions of skin and fat cause large deformations, especially on the thighs and around the knees. These large extrusions of tissue drastically inhibit mobility.
Sources: en.wikipedia.org
In 2014, when Russia-United States and Russia-NATO relations worsened over the Annexation of Crimea, the Russian state-owned television channel Russia 1 stated that "Russia is the only country in the world that is really capable of turning the USA into radioactive ash." U.S. Secretary of Defense Ash Carter considered proposing deployment of ground-launched cruise missiles in Europe that could pre-emptively destroy Russian weapons. In August 2017, North Korea warned that it might launch mid-range ballistic missiles into waters within 18 to 24 miles (29 to 39 km) of Guam, following an exchange of threats between the governments of North Korea and the United States. Escalating tensions between North Korea and the United States, including threats by both countries that they could use nuclear weapons against one another, prompted a heightened state of readiness in Hawaii. The perceived ballistic missile threat broadcast all over Hawaii on 13 January 2018 was a false missile alarm. In October 2018, the former Soviet leader Mikhail Gorbachev commented that U.S. withdrawal from the Intermediate-Range Nuclear Forces Treaty is "not the work of a great mind" and that "a new arms race has been announced". In early 2019, more than 90% of world's 13,865 nuclear weapons were owned by Russia and the United States. In 2019, Vladimir Putin warned that Russia would deploy nuclear missiles in Europe if the United States deployed intermediate-range nuclear missiles there.
== Bibliography == Move That Mountain (1976), ISBN 978-0-88270-164-6 Eight Keys to Success (1980), ISBN 978-0-89221-071-8 I Was Wrong (1996), ISBN 978-0-7852-7425-4 Prosperity and the Coming Apocalypse (1998), ISBN 978-1-4185-5422-4 The Refuge: The Joy of Christian Community in a Torn-Apart World (2000), ISBN 978-1-4185-5423-1 Time Has Come: How to Prepare Now for Epic Events Ahead (2014), ISBN 978-1-61795-134-3 You Can Make It: God's Faithfulness in Dark Times-Past, Present and Future (2021), ISBN 978-1-63641-047-0
In collaboration with the Academic Medical Center in Amsterdam, Inreda Diabetic B.V. has developed a closed loop system with insulin and glucagon. The initiator, Robin Koops, started to develop the device in 2004 and ran the first tests on himself. In October 2016 Inreda Diabetic B.V. got the ISO 13485 license, a first requirement to produce its artificial pancreas. The product itself is called Inreda AP, and soon made some highly successful trials. After clinical trials, it received the CE marking, noting that it complies with European regulation, in February 2020. In October 2020 the health insurance company Menzis and Inreda Diabetic then started a pilot with 100 patients insured by Menzis. These are all patients that face very serious trouble in regulating their blood glucose levels. They now use the Inreda AP instead of the traditional treatment. Another large scale trial with the Inreda AP was set up in July 2021, and should determine whether Dutch health insurance should cover the device for all their insured. A smaller improved version of the Inreda AP is scheduled for release in 2023.
In 1950, two Danish physicists Otto Kofoed-Hansen and Karl-Ove Nielsen discovered a new technique for producing radioisotopes which enabled production of isotopes with shorter half-lives than earlier methods. The Copenhagen experiment they carried out included a simplified version of the same elements used in modern on-line experiments. Ten years later, in Vienna, at a symposium about separating radioisotopes, plans for an 'on-line' isotope separator were published. Using these plans, CERN's Nuclear Chemistry Group (NCG) built a prototype on-line mass separator coupled to target and ion source, which was bombarded by a 600 MeV proton beam delivered by CERN's the Synchro-Cyclotron. The test was a success and showed that the SC was an ideal machine for on-line rare isotope production. The plan for an electromagnetic isotope separator was developed during 1963–4 by European nuclear physicists and, in late 1964, their proposal was accepted by the CERN Director-General and the ISOLDE project began.
Sources: en.wikipedia.org
== General bibliography == Audi, G.; Kondev, F. G.; Wang, M.; et al. (2017). "The NUBASE2016 evaluation of nuclear properties". Chinese Physics C. 41 (3) 030001. Bibcode:2017ChPhC..41c0001A. doi:10.1088/1674-1137/41/3/030001. Beiser, A. (2003). Concepts of modern physics (6th ed.). McGraw-Hill. ISBN 978-0-07-244848-1. OCLC 48965418. Hoffman, D. C.; Ghiorso, A.; Seaborg, G. T. (2000). The Transuranium People: The Inside Story. World Scientific. ISBN 978-1-78-326244-1. Kragh, H. (2018). From Transuranic to Superheavy Elements: A Story of Dispute and Creation. Springer. ISBN 978-3-319-75813-8. Zagrebaev, V.; Karpov, A.; Greiner, W. (2013). "Future of superheavy element research: Which nuclei could be synthesized within the next few years?". Journal of Physics: Conference Series. 420 (1) 012001. arXiv:1207.5700. Bibcode:2013JPhCS.420a2001Z. doi:10.1088/1742-6596/420/1/012001. ISSN 1742-6588. S2CID 55434734.
== Diagnosis == In order to assess lactose intolerance, intestinal function is challenged by ingesting more dairy products than can be readily digested. Clinical symptoms typically appear within 30 minutes, but may take up to two hours, depending on other foods and activities. Substantial variability in response (symptoms of nausea, cramping, bloating, diarrhea, and flatulence) is to be expected, as the extent and severity of lactose intolerance varies among individuals. The next step is to determine whether it is due to primary lactase deficiency or an underlying disease that causes secondary lactase deficiency. Physicians should investigate the presence of undiagnosed celiac disease, Crohn's disease, or other enteropathies when secondary lactase deficiency is suspected and infectious gastroenteritis has been ruled out. Lactose intolerance is distinct from milk allergy, an immune response to cow's milk proteins. They may be distinguished in diagnosis by giving lactose-free milk, producing no symptoms in the case of lactose intolerance, but the same reaction as to normal milk in the presence of a milk allergy. A person can have both conditions. If positive confirmation is necessary, four tests are available.
In 1972, Hughes sold the tool division of Hughes Tool Company, and reconsolidated his remaining holdings as the Summa Corporation, which included Hughes' property and other businesses. The Aircraft Division became the Hughes Helicopter Division, Summa Corp. That same year, the US Army issued a request for proposals (RFP) for an Advanced Attack Helicopter (AAH). From an initial list of 5 manufacturers Hughes Aircraft's Toolco Aircraft Division (later Hughes Helicopters) and Bell were selected as finalists. In 1975, Hughes' Model 77/YAH-64 was selected over Bell's YAH-63. First flight of a development prototype occurred in 1977. Also in 1975, Hughes engineers at began concept development work of NOTAR. In 1981, Summa's Hughes Helicopter Division was reconstituted as Hughes Helicopters, Inc.. By December, six AH-64A prototypes had been built and the Army had awarded a purchase contract to the company. Production would reach more than 1,100 by 2005. In 1983, the first production model AH-64 rolled off the production line at the company's new Mesa, Arizona facility. That same year, the company was honored by the National Aeronautic Association with the prestigious Collier Trophy. The company also licensed Schweizer Aircraft to produce the Model 300C. In January 1984, Hughes Helicopters, Inc. was sold to McDonnell Douglas by Summa Corporation, under the parent's efforts to streamline its focus and interest in real estate development. McDonnell Douglas paid $470 million for the company and made it a subsidiary.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.